Insulinoma differential diagnosis: Difference between revisions
Ahmed Younes (talk | contribs) No edit summary |
|||
(5 intermediate revisions by 3 users not shown) | |||
Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
[[Image:Home_logo1.png|right|250px|link=https://www.wikidoc.org/index.php/Insulinoma]] | |||
{{CMG}}; {{AE}} {{ADS}} | {{CMG}}; {{AE}} {{ADS}} | ||
==Overview== | ==Overview== | ||
Insulinoma must be differentiated from other diseases that cause features of [[hypoglycemia]] like [[altered mental status]]/[[confusion]], profuse [[sweating]] and visual disturbances ([[Blurred vision|blurring]]/[[diplopia]]). These are classified on the basis of [[laboratory]] findings into exogenous [[insulin]], [[oral hypoglycemic agent]]<nowiki/>s (e.g. [[ | Insulinoma must be differentiated from other diseases that cause features of [[hypoglycemia]] like [[altered mental status]]/[[confusion]], profuse [[sweating]] and visual disturbances ([[Blurred vision|blurring]]/[[diplopia]]). These are classified on the basis of [[laboratory]] findings into exogenous [[insulin]], [[oral hypoglycemic agent]]<nowiki/>s (e.g. [[Sulphonylurea]]<nowiki/>s), [[Nesidioblastosis]], insulin autoimmune hypoglycemia. | ||
==Differentiating insulinoma from other Diseases== | ==Differentiating insulinoma from other Diseases== | ||
Line 88: | Line 88: | ||
| style="background: #F5F5F5; padding: 5px;text-align: center;" | - | | style="background: #F5F5F5; padding: 5px;text-align: center;" | - | ||
|- | |- | ||
| colspan="9" style="background: #DCDCDC; padding: 5px; | | | colspan="9" style="background: #DCDCDC; padding: 5px; " | | ||
‡ Free C-peptide and proinsulin concentrations are low<br> | ‡ Free C-peptide and proinsulin concentrations are low<br> | ||
¤ [[IGF]]= Insulin Growth Factor, Increased pro-IGF-2, free [[Insulin-like growth factor 2|IGF]]-2, IGF-2/[[IGF-1]] ratio | ¤ [[IGF]]= Insulin Growth Factor, Increased pro-IGF-2, free [[Insulin-like growth factor 2|IGF]]-2, IGF-2/[[IGF-1]] ratio | ||
Line 94: | Line 94: | ||
|} | |} | ||
'''Differentiating hypoglycemia from other diseases that cause autonomic hyperactivity symptoms :''' | |||
'''Differentiating hypoglycemia from other diseases that cause autonomic hyperactivity symptoms | |||
{| | {| | ||
|+ | |+ | ||
Line 105: | Line 104: | ||
! rowspan="2" style="background: #4479BA; color: #FFFFFF; " |Signs | ! rowspan="2" style="background: #4479BA; color: #FFFFFF; " |Signs | ||
|- | |- | ||
! style="background: #4479BA; color: #FFFFFF; "|Palpitations | ! style="background: #4479BA; color: #FFFFFF; " |Palpitations | ||
! style="background: #4479BA; color: #FFFFFF; "|Fever | ! style="background: #4479BA; color: #FFFFFF; " |Fever | ||
! style="background: #4479BA; color: #FFFFFF; "|Sweating | ! style="background: #4479BA; color: #FFFFFF; " |Sweating | ||
! style="background: #4479BA; color: #FFFFFF; "|Headache | ! style="background: #4479BA; color: #FFFFFF; " |Headache | ||
|- | |- | ||
[[ | ! style="background: #DCDCDC; text-align: center;" |[[Hypoglycemia]] | ||
| + | | style="background: #F5F5F5; text-align: center;" | + | ||
| - | | style="background: #F5F5F5; text-align: center;" | - | ||
| + | | style="background: #F5F5F5; text-align: center;" | + | ||
| + | | style="background: #F5F5F5; text-align: center;" | + | ||
| | | style="background: #F5F5F5; " | | ||
* [[Tachycardia]] | * [[Tachycardia]] | ||
* Blurred vision | * Blurred vision | ||
Line 121: | Line 120: | ||
* [[Tremor|Tremors]] | * [[Tremor|Tremors]] | ||
* [[Seizures]]/ [[Coma]] | * [[Seizures]]/ [[Coma]] | ||
| | | style="background: #F5F5F5; " | | ||
* Plasma [[glucose]] <70 mg/dL | * Plasma [[glucose]] <70 mg/dL | ||
* S. [[Insulin]] | * S. [[Insulin]] | ||
Line 181: | Line 180: | ||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} | ||
[[Category:Up-To-Date]] | |||
[[Category:Oncology]] | |||
[[Category:Medicine]] | |||
[[Category:Gastroenterology]] | |||
[[Category:Surgery]] |
Latest revision as of 21:26, 8 February 2019
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Amandeep Singh M.D.[2]
Overview
Insulinoma must be differentiated from other diseases that cause features of hypoglycemia like altered mental status/confusion, profuse sweating and visual disturbances (blurring/diplopia). These are classified on the basis of laboratory findings into exogenous insulin, oral hypoglycemic agents (e.g. Sulphonylureas), Nesidioblastosis, insulin autoimmune hypoglycemia.
Differentiating insulinoma from other Diseases
Insulinoma must be differentiated from other diseases that cause features of hypoglycemia. These are classified on the basis of laboratory findings.
Differentials for Hypoglycemia on the basis of Laboratory findings:[1]
Diagnoses | Laboratory Findings differentiating among causes of Hypoglycemia | |||||||
---|---|---|---|---|---|---|---|---|
S.Glucose (mg/dL) |
C Peptide (pmol/L) | S.Insulin (μU/mL) | S.Proinsulin (pmol/L) |
S. Beta hydroxybutyrate | Glucose increase after glucagon(mg/dL) | Oral Hypoglycemic agent | Antibodies to Insulin | |
Normal/Fasting | <55 | <200 | <3 | <5 | >2.7 | <25 | - | - |
Exogenous Insulin | <55 | <200 | >>3 | <5 | ≤2.7 | >25 | - | - |
Insulinoma | <55 | ≥200 | ≥3 | ≥5 | ≤2.7 | >25 | - | - |
Nesidioblastosis | ||||||||
Post gastric bypass hypoglycemia (PGPH) | ||||||||
Insulin autoimmune hypoglycemia | <55 | >>200‡ | >>3 | >>5‡ | ≤2.7 | >25 | - | + |
Oral hypoglycemic agent | <55 | ≥200 | ≥3 | ≥5 | ≤2.7 | >25 | + | - |
IGF¤ | <55 | <200 | <3 | <5 | ≤2.7 | >25 | - | - |
‡ Free C-peptide and proinsulin concentrations are low |
Differentiating hypoglycemia from other diseases that cause autonomic hyperactivity symptoms :
Disease | Clinical Manifestation | Investigations | ||||
---|---|---|---|---|---|---|
Symptoms | Signs | |||||
Palpitations | Fever | Sweating | Headache | |||
Hypoglycemia | + | - | + | + |
|
|
Anxiety disorders | + | - | + | + |
|
|
Pheochromocytoma | + | + | + | + |
|
|
Arrhythmia | + | - | - | - |
|
|
Hyperthyroidism | + | + | + | + |
|
|
References
- ↑ Cryer PE, Axelrod L, Grossman AB, Heller SR, Montori VM, Seaquist ER; et al. (2009). "Evaluation and management of adult hypoglycemic disorders: an Endocrine Society Clinical Practice Guideline". J Clin Endocrinol Metab. 94 (3): 709–28. doi:10.1210/jc.2008-1410. PMID 19088155.
- ↑ Lenders JW, Pacak K, Walther MM, Linehan WM, Mannelli M, Friberg P; et al. (2002). "Biochemical diagnosis of pheochromocytoma: which test is best?". JAMA. 287 (11): 1427–34. PMID 11903030.
- ↑ Bravo EL (1991). "Pheochromocytoma: new concepts and future trends". Kidney Int. 40 (3): 544–56. PMID 1787652.